Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
Status:
Withdrawn
Trial end date:
2022-01-21
Target enrollment:
Participant gender:
Summary
Part A: Primary objective is to determine the effects of BIIB095 on nerve excitability in
healthy participants. Secondary and exploratory objectives include determining the effects of
BIIB095 on nerve excitability in diabetic polyneuropathy (DPN) and assessing the safety,
tolerability and pharmacokinetics of BIIB095.
Part B (optional): Equivalent objectives are pursued for BIIB074.